Related references
Note: Only part of the references are listed.VEGF pathway inhibition potentiates PARP inhibitor efficacy in ovarian cancer independent of BRCA status
Francesca Bizzaro et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Quantitative imaging of RAD51 expression as a marker of platinum resistance in ovarian cancer
Michal M. Hoppe et al.
EMBO MOLECULAR MEDICINE (2021)
PARP-inhibitors in epithelial ovarian cancer: Actual positioning and future expectations
Helene Vanacker et al.
CANCER TREATMENT REVIEWS (2021)
The Role of PARP Inhibitors in the Ovarian Cancer Microenvironment: Moving Forward From Synthetic Lethality
Margherita Turinetto et al.
FRONTIERS IN ONCOLOGY (2021)
The rediscovery of platinum-based cancer therapy
Sven Rottenberg et al.
NATURE REVIEWS CANCER (2021)
Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer
Neha Chopra et al.
NATURE COMMUNICATIONS (2020)
Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial
Paul DiSilvestro et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer
R. E. Miller et al.
ANNALS OF ONCOLOGY (2020)
Homologous recombination deficiency real-time clinical assays, ready or not?
Katherine Fuh et al.
GYNECOLOGIC ONCOLOGY (2020)
Clinical assays for assessment of homologous recombination DNA repair deficiency
Elizabeth H. Stover et al.
GYNECOLOGIC ONCOLOGY (2020)
Impact of ERCC1, XPF and DNA Polymerase β Expression on Platinum Response in Patient-Derived Ovarian Cancer Xenografts
Federica Guffanti et al.
CANCERS (2020)
PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline COMMENT
[Anonymous]
OBSTETRICAL & GYNECOLOGICAL SURVEY (2020)
PARP inhibition and immune modulation: scientific rationale and perspectives for the treatment of gynecologic cancers
Elizabeth K. Lee et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)
PARP inhibitors in ovarian cancer
Elisena Franzese et al.
CANCER TREATMENT REVIEWS (2019)
PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers
Patrick G. Pilie et al.
CLINICAL CANCER RESEARCH (2019)
Epithelial ovarian cancer
Stephanie Lheureux et al.
LANCET (2019)
A decade of clinical development of PARP inhibitors in perspective
J. Mateo et al.
ANNALS OF ONCOLOGY (2019)
Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
A. Gonzalez-Martin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Platinum Resistance in Ovarian Cancer: Role of DNA Repair
Giovanna Damia et al.
CANCERS (2019)
Overcoming platinum-acquired resistance in ovarian cancer patient-derived xenografts
Francesca Ricci et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2019)
RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer
C. Cruz et al.
ANNALS OF ONCOLOGY (2018)
Ovarian Cancer Statistics, 2018
Lindsey A. Torre et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Targeting deubiquitinase USP28 for cancer therapy
Xiaofang Wang et al.
CELL DEATH & DISEASE (2018)
Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance
Stephen J. Pettitt et al.
NATURE COMMUNICATIONS (2018)
Platinum sensitivity and DNA repair in a recently established panel of patient-derived ovarian carcinoma xenografts
Federica Guffanti et al.
Oncotarget (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Mechanisms of PARP inhibitor sensitivity and resistance
Alan D. D'Andrea
DNA REPAIR (2018)
Base and nucleotide excision repair facilitate resolution of platinum drugs-induced transcription blockage
Jana Slyskova et al.
NUCLEIC ACIDS RESEARCH (2018)
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
Marta Castroviejo-Bermejo et al.
EMBO MOLECULAR MEDICINE (2018)
HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures
Helen Davies et al.
NATURE MEDICINE (2017)
Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer
Petra ter Brugge et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Landscape of somatic mutations in 560 breast cancer whole-genome sequences
Serena Nik-Zainal et al.
NATURE (2016)
Repair Pathway Choices and Consequences at the Double-Strand Break
Raphael Ceccaldi et al.
TRENDS IN CELL BIOLOGY (2016)
Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer
Petra ter Brugge et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2016)
Profiling cancer gene mutations in longitudinal epithelial ovarian cancer biopsies by targeted next-generation sequencing: a retrospective study
L. Beltrame et al.
ANNALS OF ONCOLOGY (2015)
A Unique Subset of Epithelial Ovarian Cancers with Platinum Sensitivity and PARP Inhibitor Resistance
Raphael Ceccaldi et al.
CANCER RESEARCH (2015)
Biology of Poly(ADP-Ribose) Polymerases: The Factotums of Cell Maintenance
Peter Bai
MOLECULAR CELL (2015)
REV7 counteracts DNA double-strand break resection and affects PARP inhibition
Guotai Xu et al.
NATURE (2015)
Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
Panagiotis A. Konstantinopoulos et al.
CANCER DISCOVERY (2015)
Patient-Derived Ovarian Tumor Xenografts Recapitulate Human Clinicopathology and Genetic Alterations
Francesca Ricci et al.
CANCER RESEARCH (2014)
Integrated genomic analyses of ovarian carcinoma
D. Bell et al.
NATURE (2011)
53BP1 Inhibits Homologous Recombination in Brca1-Deficient Cells by Blocking Resection of DNA Breaks
Samuel F. Bunting et al.
CELL (2010)
Verification of complete bisulfite modification using Calponin-specific primer sets
Ruethairat Sriraksa et al.
CLINICAL BIOCHEMISTRY (2010)
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
HE Bryant et al.
NATURE (2005)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
H Farmer et al.
NATURE (2005)
Share Paper
